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Abstract
Complete response (CR) rates reported for cytotoxic chemotherapy for
late-stage cancer patients are generally low, with few exceptions, regardless of
the solid cancer type or drug regimen. We investigated CR rates reported in the
literature for clinical trials using chemotherapy alone, across a wide range of
tumour types and chemotherapeutic regimens, to determine an overall CR rate
for late-stage cancers. A total of 141 reports were located using the PubMed
database. A meta-analysis was performed of reported CR from 68
chemotherapy trials (total 2732 patients) using standard agents across
late-stage solid cancers—a binomial model with random effects was adopted.
Mean CR rates were compared for different cancer types, and for
chemotherapeutic agents with different mechanisms of action, using a logistic
regression. Our results showed that the CR rates for chemotherapy treatment
of late-stage cancer were generally low at 7.4%, regardless of the cancer type
or drug regimen used. We found no evidence that CR rates differed between
different chemotherapy drug types, but amongst different cancer types small
CR differences were evident, although none exceeded a mean CR rate of 11%.
This remarkable concordance of CR rates regardless of cancer or therapy type
remains currently unexplained, and motivates further investigation.
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Introduction
Despite intense efforts to improve treatment of advanced cancer 
over many years with numerous cytotoxic agents and dose regi-
mens, some observers have reported that there has been little sub-
stantial improvement in treatment outcomes over the last several 
decades for most cancer types1–5. Several notable exceptions exist, 
where more successful clinical remission and even cure rates have 
been shown using chemotherapeutic approaches, such as for tes-
ticular cancer using platinum-based agents, and acute childhood 
leukaemia using vinca alkaloids6–9. Unfortunately, the same has not 
been true for most other advanced solid malignancies that cause 
mortality in an estimated 160,000 cancer patients per week interna-
tionally, with over 11,000 cancer deaths per week in the USA10.
In 2006, Kiberstis and Travis1 commented that “An examination of 
the annual statistical data compiled by the American Cancer Society 
quickly reveals that the rate of mortality from cancer has changed 
very little over the past 50 years,” showing little departure from a 
point made by Bailar2 from a mortality evaluation of the national 
cancer program between 1950 and 1990, stating “In the end, any 
claim of major success against cancer must be reconciled with this 
[increasing U.S. mortality] figure. I do not think such reconciliation 
is possible and again conclude, as I did seven years ago, that our 
decades of war against cancer have been a qualified failure.” Again 
in 1997, Bailar and Gornik commented, “Observed changes in mor-
tality due to cancer primarily reflect changing incidence or early 
detection. The effect of new treatments for cancer on mortality has 
been largely disappointing”2.
This lack of progress persists despite efforts to improve fundamental 
understanding of cancer growth models11–14, 1.56 million published 
papers, and around US $200 billion expenditure on cancer research 
up until 2006 in the US alone, since the National Cancer Act was 
passed in 19711. This suggests a problem might exist with the cur-
rent paradigm and the assumption that cytotoxic chemotherapies are 
acting against cancer cells per se, rather than by some other mecha-
nism. In 2010, Lawrence Baker, Professor of Internal Medicine and 
Michigan Medical School and Chairman of the Southwest Oncol-
ogy Group stated, “I am trying to get people to stop saying how 
successful the cancer research enterprise is, it is not true” and “Cure 
is clearly the expectation of society”4. Cure, or long-term survivals, 
are associated with the relatively rare event of complete response 
(CR), where all cancer disappears as a result of chemotherapy.
The above statements are significant when considering standard 
chemotherapy where CR rates, in late-stage disease, are particu-
larly static and therefore disappointing. Using breast cancer as an 
example, Frasci et al.15 recently reported from the Milan NCI 
experience, a 7% pathological complete response (pCR) rate using 
neo-adjuvant combined doxorubicin-paclitaxel and 6% CR rate for 
advanced breast cancer using an anthracycline-based regimen16. In 
1581 patients treated between 1973 and 1982 with consecutive first-
line standard-dose doxorubicin and alkylating agent combinations, 
263 (16.6%) patients achieved a CR and 49 (3.1%) remained disease 
free for more than 5 years, and 26 patients (1.5%) remained in first 
CR at 15 years median follow-up17. A recent study of 2100 patients 
in 42 phase II trials (70 trial arms) using cytotoxic chemotherapy 
for metastatic melanoma that completed accrual in the years from 
1975 to 2006, conducted by the Southwest Oncology Group, Eastern 
Cooperative Oncology Group, Cancer and Leukemia Group B, 
North Central Cancer Treatment Group, and the Clinical Trials 
Group of the National Cancer Institute of Canada, showed no sta-
tistically significant change in progression free survival, or in long-
term overall survival over this time period18.
Chemo-resistance metabolic pathways have been widely assumed 
to be the reason for the development of reduced cytotoxicity against 
many tumor types19, and may be part of the answer. Clonal genetic 
diversity and clonal outgrowth of less chemo-susceptible tumor 
clones is another explanation that has been advanced, related to the 
existence of tumor stem-cells with the capacity to better adapt and 
grow in response to environmental selection pressure20,21. These 
theories have led to the development of increased dosage regimens, 
high-intensity dosing, more frequent-dosing regimens, high-dose 
myelo-ablative chemotherapy with cellular re-infusion methods, 
and the use of multiple agent chemotherapy regimens. All have 
become popular in standard medical oncology practice, but there 
remains little evidence that more chemotherapy is better in terms of 
clinical outcomes—undesirable toxicity to normal tissues is often 
a significant problem for the patient, causing treatment limitations 
and considerable cost in economic and human terms22. Moreover, 
CR rates and overall survival have not appreciably improved for 
most individual cancer types, and to our knowledge, wider analysis 
of CR rates across many different cancer types, or chemotherapy 
drug types, has not been performed.
Rationale
Few studies have addressed the reported CR rates over time for 
systemic cytotoxic chemotherapeutic treatment across a broad 
range of advanced solid tumours in a systematic manner. System-
atic meta-analysis of CR rates across the spectrum of solid tumours 
and cytotoxic drug types appeared to be lacking in the literature.
Objective
The objective was to investigate CR rates reported in the literature 
in clinical trials for advanced cancer treatment across a wide range 
of cancer types and chemotherapeutic regimens used to date, by 
conducting a meta-analysis to compare the CR rates and to deter-
mine an overall CR rate.
Materials and methods
We performed this meta-analysis in accordance with the guide-
lines of the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA)23.
Eligibility criteria
Studies were considered initially eligible for evaluation if they 
were published on the recognized PubMed database, in the English 
language, and accessible in abstract form. Only full text studies 
with reported valid randomized series of cases of advanced can-
cer, treated by described methods of chemotherapy administra-
tion alone without concomitant surgery or radiotherapy—both of 
which may confound data interpretation—and clearly reported CR 
rates were included, published between 2000 and 2006 inclusive. 
Study follow-up had to be of sufficient length to permit adequate 
assessment of CR rates.
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Information sources
The available literature was searched using the PubMed database 
(http://www.ncbi.nlm.nih.gov/pubmed/), hosted by the National 
Center for Biotechnology Information (NCBI), U.S. National 
Library of Medicine. The search date range was 1st January 2000 
to 31st December 2006. This time period “snapshot” was chosen 
commencing in 2000 because of improved standardization of clini-
cal trial response rate reporting after 1999 with the publication of 
RECIST criteria24 and before the introduction of newer pathway 
blocking ‘targeted’ agents from 2007 onwards, which progressively 
were added to chemotherapy agents, and might have confounded 
the analysis.
Search
The following search terms “phase 2/3”, “chemotherapy”, “cancer”, 
“late stage”, and “complete response” were used. To increase the 
specificity of the query, specific chemotherapy agents (eg. vinblast-
ine, Taxol, cisplatin, 5FU) were included in the search criteria. The 
search was restricted to clinical trials, reported in English. Using 
these criteria, 141 candidate trials were identified by abstract. 
A spreadsheet containing the gathered data is included in the 
Supplemental material S1.
Study selection
Three analysts (MLA, SLY-C and BJC) independently examined 
those studies that were reported in journals that were accessible by 
the authors. The CR rates had to be recorded in sufficient detail to 
enable assessment. Trials involving chemotherapy in combination 
with surgery or radiotherapy were excluded in order to observe clin-
ical responses to chemotherapy alone. Trials were also excluded if 
their reported response rates in the text were inconsistent with pre-
sented data. Disagreements between the analysts about exclusions 
were resolved by discussion. After exclusions, sixty-eight clinical 
trials with a total of 2732 assessable patients remained25–92.
Data collection process
Data was extracted as already outlined, using a preliminary screen 
of two analysts identifying the content validity of each study: 
advanced cancer, numbers of patients >10 and use of a chemo-
therapeutic agent or agents alone—with no potentially confounding 
surgery/radiotherapy or other treatments—for suitable follow-up to 
clearly report any CR rate. Full texts were obtained and a third ana-
lyst scrutinized the papers for the details to verify that the abstract 
CR rates and reported cases were accurately reported. Any paper 
that could not meet the above criteria or was otherwise unable to 
be validated was excluded by agreement. Any discrepancy was 
solved by repeated review, discussion and agreement. Data was 
collected in a spreadsheet, de-identified and used for statistical 
analysis.
Risk of bias in individual studies
To investigate the risk of possible bias in individual clinical trial 
studies, we relied on standardized reporting methods of clinical 
trial results as outlined by WHO and RECIST response rate criteria 
introduced in 200024. The assumption being, all trials would expe-
rience similar occurrence of overstatement or understatement of 
efficacy. As a preliminary guide, to assess feasibility and whether 
our exclusion criteria might represent bias, we carried out an 
analysis of CR and Partial Response (PR) data from the published 
abstracts on the full 130 clinical trials initially identified as eligible. 
This resulted in an average CR rate of 8.3%, which suggested that 
more detailed analysis was both feasible and likely to not represent 
appreciable bias.
Summary measures
The summary measures used in these studies are the mean CR rate 
separately determined from meta-analysis of (i) included studies 
across all cancer types, and (ii) across different primary drug group 
types specified according to the overall mode of action of each drug 
type used in the relevant study.
Synthesis of results
Clinical trial data were entered into a spreadsheet—this spreadsheet 
can be openly accessed in the Supplemental material S1. Fields 
recorded for each of the 68 trials include: inclusion/exclusion, 
%CR, %PR, cancer type, drug type, journal citation etc.
The data were analyzed using a random-effects binomial distribu-
tion meta-analysis, for which the response variable was the pro-
portion of patients that were reported to achieve a CR. Separate 
random-effects binomial distribution meta-analyses were also per-
formed by tumor type and by primary drug type.
We also applied a generalized linear model to the observed number 
of complete responders for each study, assuming that the distribu-
tion of the response variable was conditionally binomial, and using 
the logit link function. We tested the effects of tumor type and pri-
mary drug type using marginal likelihood ratio tests, that is, each 
effect was tested with the other included in the model. The analyses 
were all performed in R version 2.11.1 (http://www.r-project.org), 
an open-source statistical environment93.
Risk of bias across studies
To investigate the risk of possible bias by individual clinical trial 
studies, we undertook a sensitivity analysis. This revealed a sur-
prising consistency of ~7% average CR rate. This suggests, that 
although the population study with respects to cancer type, age, sex 
of patient and drugs used, were heterogeneous, the CR rate was 
fixed or stable at ~7%. To illustrate the possible effects of publica-
tion bias we have generated a standard funnel plot94,95, as shown 
in Figure 1. Here we see, the cohort size N for each chemotherapy 
trial on the vertical axis and the fraction of the cohort with CR on 
the horizontal axis. The red vertical line represents the average of 
the CR fraction = 0.0706, which corresponds to 7.06%. By visual 
inspection overall skew in the plot is small, and thus the effects of 
publication bias appear to be minimal for this study.
Additional analyses
In addition, as a preliminary measure, to see if our exclusion crite-
ria were feasible and whether any bias might exist, we carried out 
exactly the same analysis on the full 141 clinical trials from CR and 
PR data in the initial identified published abstracts.
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Results
Study selection
Referring to the flow chart in Figure 2, we see that from 141 records 
resulting from the PubMed database search, 11 were not accessible 
as full text. Of the remaining 130, only 68 of these, without either 
missing or incomplete data, were evaluable. The 62 exclusions 
were due to small numbers of patients in the study, treatment of 
patients by surgery, difficulty substantiating the conclusions from 
the data provided, or absence of information on precise CR or PR 
rates. Exclusion were due to: (i) errors or inconsistencies appeared 
present, (ii) ambiguity in the patient numbers was detected, 
(iii) unclear staging, (iv) non-advanced cancer was included, or 
(v) surgery was used—sometimes post-chemotherapy. The final 68 
papers were checked for duplicate studies. None were found, and 
thus no further exclusions were made on this basis.
Study characteristics
Our analyses involved 68 trials and included studies across more 
than 10 different cancer types and 7 different cytotoxic drug types. 
These included by (a) cancer type; squamous cell carcinoma (9 tri-
als), renal cell carcinoma (1) prostate (3), pancreatic carcinoma (6), 
ovarian carcinoma (11), other carcinoma (9), non-small cell lung 
Figure 1. Funnel plot to check for publication bias. For each of the 68 chemotherapy trials, the size N of the cohort is plotted on the vertical 
axis. On the horizontal axis the fraction of the cohort that displayed complete response (CR) is plotted. The red vertical line represents the 
average of the CR fraction = 0.0706, which corresponds to 7.06%. A standard deviation each side of the average is represented by the curved 
red lines, calculated by assuming a binomial model. The points appear to be clustered in bands, due to the affect of data quantisation—this 
is due to the fact that integer numbers of patients have a CR. Thus the first band of points, toward the bottom left of the graph, represent all 
the trials with a total CR = 1 person, the next band represents all the trials with total CR = 2 people, and so on. For higher total CR numbers, 
the bands do not appear due to the sparsity of data for large trials. On the funnel plot we see a large spread in CR fraction for 6 trials that are 
optimistically over a standard deviation, however, the overall skew is nevertheless small. Thus the effects of publication bias appear to be 
minimal for this study.
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Figure 2. Flow chart summarizing the literature search and study selection for the meta-analysis. The final 68 studies represented a 
total of 2732 patients.
carcinoma (4), mesothelioma (1), melanoma (4), gastric carcinoma 
(6), colorectal carcinoma (6), breast carcinoma (6) and brain malig-
nancies (2); and by (b) primary drug type; topoisomerase inhibitor 
(TPI), T-Cell cytokine inhibitor (cyclosporine) (TCCi), spindle poi-
son (SP), nucleoside analogue (NA), DNA/RNA synthesis inhibitor 
(DRsi), antimetabolite (AM), alkylating agent (ALK), antibiotic (AB).
Synthesis of results
The total number of assessable patients was 2732, of which a total 
of 193 were classified as complete responders (7.41%). A total of 
768 patients were reported as partial responders (28.1%).
Individual estimates of mean CR rates within the cancer type group-
ings were: SCC (10.97%); RCC (8.12%); Prostate (10.9%); Pancre-
atic (3.2%); Ovarian (6.08%); Other (10.57%); NSCLC (5.02%); 
Mesothelioma (6.33%); Melanoma (8.48%); Gastric (6.79%); 
Colorectal (6.71%); Breast (10.14%); Brain (6.45%). These are 
shown collectively in Figure 3.
The overall meta-analysis estimate of the CR rate from random-
effects was 7.41%, [95% confidence intervals (6.27%, 8.64%)].
A generalized linear model that was fitted to the CR rates found 
a statistically significant relationship between cancer type and CR 
rate (χ2 = 23.0 on 12 d.f., p = 0.028) and no evidence of a statisti-
cally significant relationship between drug type/regimen and CR 
rate (χ2 = 7.87 on 7 d.f., p = 0.343).
Despite the statistically significant difference between cancer types, 
the mean CR rates for each individual cancer type only ranged from 
3.2% (pancreatic cancer) to 10.9% (prostate cancer)—see Figure 3.
The ‘other carcinoma’ group comprised cancers of the biliary tract, 
cervix, uterus, salivary gland, urothelium, and small-cell lung carci-
noma. The number of chemotherapy trials using a single agent alone 
was 17, while the remainder used more than one agent. The number of 
patients in each trial ranged from 10 to 134, with a median of 37.5.
Clinical trial records identified
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Discussion
The complete response (CR) rate has unfortunately remained 
relatively static for most advanced solid cancers for many dec-
ades despite major improvements in understanding considerable 
new information concerning the molecular genetics, intracellular 
pathways, adhesion mechanisms, stromal characteristics, angio-
genesis, metastatic processes, and immunology, relating to many 
cancer cell types and modalities of treatment. Similarly, advances 
in organic chemistry, molecular structural crystallography, synthe-
sis, and pharmaceutical production have not led to expected rapid 
advances. Numerous different, often quite ingenious, approaches 
have failed to significantly improve CR rates for survival in patients 
with advanced cancers20. With this in mind we performed a meta-
analysis of existing trials and treatment modalities across most 
common cancer types over the seven years between 2000 and 2006 
inclusive.
Summary of evidence
In this paper, we report the results of a meta-analysis of 68 chemo-
therapy trials for cancer treatment, in which we sought to evaluate 
the CR rate for late-stage cancer patients receiving chemotherapy, 
embracing a wide variety of solid tumors and drug types. Overall, 
the CR rate for patients with most types of late-stage cancers receiv-
ing chemotherapy are between 5% and 10%. Our meta-analysis 
suggests that the CR rate for patients with most types of late-stage 
cancers receiving chemotherapy are between 5% and 10% across 
many cancer types, with an actual mean CR rate of 7.41% approxi-
mately bisecting this estimated range.
This study did not set out to include cancers that represent rare 
notable exceptions, such as testicular carcinoma and childhood 
acute lymphoblastic leukemia, which are known to be highly 
chemo-responsive with CR rates of around 80–90%8,9. However, 
most advanced solid tumors in adults (eg. colon, breast, pros-
tate, melanoma, lung) are unfortunately typically lethal with CR 
rates that are almost reciprocal to those mentioned. The common 
advanced solid cancers, therefore, formed the focus of the present 
meta-analysis.
The CR rate was surprisingly concordant across the trials despite 
wide differences in tumor type, chemotherapy combination and 
mechanism of drug action. This suggests that the range of agents 
being used is low in direct anti-tumor activity. That finding has been 
explained by possible development of ‘chemo-resistance’, however, 
it appears to occur in about 93% of patients for the majority of 
tumour types and agents. An alternative explanation is interference 
with the host immune system in an adverse manner, which would 
abrogate generation or perhaps diminish the effectiveness of an 
existing anti-tumor immune response96. Many systemically admin-
istered chemotherapeutic agents exert their effects non-specifically 
on many rapidly dividing tissues other than the cancer itself. Anti- 
angiogenic activity or direct injury to intra-tumoral blood vessels 
Figure 3. Estimates (red points) and 95% confidence intervals (grey bars) for meta-analyses. These are for (a) Cancer type (SCCa = 
Squamous cell carcinoma; RCC = renal cell carcinoma; NSCLC = non-small cell lung carcinoma) and by (b) Primary drug type, (abbreviation 
key; TPI = Topoisomerase inhibitor, TCCi = T-Cell Cytokine inhibitor (Cyclosporine), SP = Spindle poison, NA = Nucleoside analogue, DRsi = 
DNA/RNA synthesis inhibitor, AM = Antimetabolite, ALK = Alkylating Agent, AB = Antibiotic). The thin vertical blue line denotes a 7.4% CR 
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has been proposed as the mechanism of action of some agents, 
while others induce DNA or mitochondrial damage.
Unfortunately, selectivity for the malignant cells in vivo is often 
poor and it has been widely appreciated that injury to normal tis-
sues occurs together with tumor cell damage, causing typical side 
effects such as nausea, diarrhea, marrow suppression, stomatitis, 
mucositis, and hair loss22. Some of these may be dose limiting and 
often significantly reduce the quality of life of the patient. In addi-
tion to marrow suppressive effects, recent data indicates that the 
immune system is often injured during chemotherapy treatment, 
with reduction in the white blood cell count being commonly noted. 
Leucopaenia may be severe, but is sometimes more subtle, and 
in particular T-cells can be ablated20. Subsets of rapidly dividing 
T-cells may be particularly vulnerable to injury, and paradoxically, 
may be even more susceptible than the cancer cells. If the ablated 
cells are effector T-cells, then any effective immune response may 
be eliminated or reduced. However, if regulatory T-cells are selec-
tively ablated or depleted, then the T-effector response may be 
enhanced96–98. Global depletion of both groups of T-cells may also 
result in the reduced ability to mount an effective immune response, 
and this may possibly ‘re-set’ the immune response.
A total of 768 patients were reported as partial responders, with an 
estimated partial response rate from the meta-analysis of 27.9%—
and when combined with complete responders (CR + PR) provid-
ing an overall response rate of 35.3%. Effectively, 64.7% of patients 
were ‘non-responders’ to therapy by not achieving a measurable 
clinical response. The heterogeneity of clinical responses might rea-
sonably be explained by the random manipulation of the immune 
system being determined by mathematical probability when chem-
otherapeutic regimens are randomly applied without consideration 
of which particular subsets of susceptible immunological cells are 
actively proliferating at the time of each dosing20,96–100.
In order to be confident that our systematic exclusions did not skew 
the results unreasonably, we repeated the meta-analysis using the 
abstracts from the full complement of 130 papers for which suit-
able CR results were provided within the summaries. The estimated 
CR rate was 8.43%, with 95% confidence interval (7.18%, 9.78%), 
which differed only slightly from the rate reported for the studies 
that were within the scope of the full-article 68 trial meta-analysis.
Limitations
The following caveats should be considered when interpreting our 
results. Inevitably, the definition of CR varied slightly amongst 
some studies. The CR was usually defined as complete regression 
of all detectable tumour clinically or radiologically, while PR was 
defined more variably. The studies were not necessarily a random 
sample because they were selected from the PubMed database 
between 2000 and 2006 and required full-text availability with ade-
quate data for the purposes of the current studies, introducing the 
potential for inadvertent selection and publication bias. However, 
every effort was made to avoid this problem. Finally, the analyses 
included here were the reported clinical response statistics rather 
than the reported rate estimates and confidence intervals. Hence the 
analysis might conflict with those reported in the actual paper. A 
larger study may overcome/diminish such biases.
Another point is that this study is limited to papers from the 
PubMed database. The usual recommendation for meta-analyses is 
to use multiple databases101. However, this is with the intention of 
mitigating against the omission of negative results that may bias 
association studies (eg. establishing a positive association between 
a cancer and a genetic marker). However, this paper is not an asso-
ciation study; we are merely demonstrating the observation that 
complete response rates for chemotherapy are low across a reason-
ably broad range of literature. The funnel plot in Figure 1 demon-
strates lack of bias as there are roughly equal numbers of points 
higher and lower than the two standard deviation lines.
Conclusions
The knowledge gained from this meta-analysis offers a broad view 
of the effects of chemotherapy on CR rates for cancers of specific 
types; collectively for many types of cancers; and for chemother-
apy agents with different mechanisms of action. It is particularly 
noteworthy that the confidence intervals lie progressively closer to 
the respective mean CR rate for the agents that have historically 
been in use for the longest time and for which the most clinical 
trial data exists. This indicates that the agents that have been in use 
the longest time have a ’real’ CR rate that approximates 7%—an 
interesting result despite years of use of these agents, even in multi-
ple combination regimens. The potential for variability amongst the 
individual clinical studies included in the meta-analysis is recog-
nized, however, selection of higher quality valid clinical trials using 
chemotherapy alone as the sole treatment modality aimed to reduce 
the natural heterogeneity amongst the studies. In this meta-analysis 
we further sought to include many cancer types to purposely exam-
ine CR rates within a spectrum of cancers. The data offer what we 
contend is a relatively unbiased and ‘clean’ view of representative 
‘real world’ clinical data, from a wide range of sources—indicative 
of true international clinical experience. The funnel plot indicates 
that this objective satisfies optimal minimisation of publication 
bias.
The significance of the results of our meta-analysis are that across 
different tumour types, and regardless of different chemotherapy 
agents/approaches, the CR rates to cancer have remained essen-
tially static and locked at about 7%, despite over 7 years of diligent 
clinical effort during which these trials were conducted. This might 
suggest that probabilistic effects are operating to mathematically 
restrict the ability to manipulate the clinical CR rate—if this can 
be further understood or overcome, CR rates may potentially be 
capable of being significantly increased.
The data might offer an alternative approach to thinking about the 
possible mechanisms of action of chemotherapy, irrespective of 
their direct effects on the tumour cells. In considering the consist-
ently low mean CR rates of 7.4% across many tumor types, and 
using different chemotherapy agents, the findings are suggestive 
that the paradigm of chemotherapy directly acting for tumour cell 
killing per se, might be incorrect. Rather, the effects of chemother-
apy on immunological cells at any point in time may be of con-
siderable significance, depending on whether rapidly proliferating 
T-effector cells or T-regulatory cell subgroups are selectively ablated 
by cytotoxicity, as has been reported in some mouse studies99,100. 
The balance of the anti-tumor immune response may be pivotally 
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controlled by the relative ablation of either effector or regulatory 
cell populations, and thereby determine the growth or destruction of 
the tumor. Indeed, higher doses of cytotoxics might ablate effector 
T-cells, thereby blunting the immune response and the ability of the 
patient’s own immune system to be effective. The recent findings 
concerning the efficacy of metronomic low-dose chemotherapies, 
administered more frequently, regularly and chronically, would also 
suggest that the immune system may be pivotal in determining the 
anti-tumor effect and clinical outcome of the patient102.
We are currently taking this approach clinically with some success, 
and are actively investigating the possible timing of chemotherapy 
and immunotherapy103–105. Optimally timed doses are capable of 
manipulating the immune response by selective immuno-stimulation 
or immuno-ablation. The intention is to maximize the in-vivo 
T-effector response, while minimizing the T-regulatory responses, 
within the patient, to provide a potential means of synchronizing 
the ongoing immune response in the patient for improving clinical 
outcome20,96.
The main finding of this study is the remarkable concordance of CR 
rates amongst studies of patients with different cancer types, and 
also amongst a range of cytotoxic chemotherapy types. This notable 
similarity in CR rates regardless of cancer or therapy type remains 
currently unexplained, and requires further intensive investigation.
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 Gábor Balázsi
The Louis and Beatrice Laufer Center for Physical and Quantitative Biology, Stony Brook University,
Stony Brook, NY, USA
The statistical analysis is appropriate and rigorous. The results are interesting – similar rates of CR for a
variety of cancers and drug types. I would like to recommend indexation after a few minor comments have
been addressed:
It would be interesting and important to include a statement on the rate of Spontaneous Regression
(tumour regressing without any treatment). This could simply be extracted from previous
publications (no additional analysis needed). This would answer the question: does chemotherapy
provide any benefit compared to no treatment at all? It would be interesting to add a sentence on
comparing the rates of CR and SR.
 
In the Introduction, a sentence on the molecular mechanisms (such as gene regulation) leading to
metastasis would be useful. A relevant citation could be Lee (2014).et al. 
 
It would also be interesting to add a sentence on any trends observable over time. If the data are
insufficient to make a statement, then the authors should write a sentence stating that.
References
1. Lee J, Lee J, Farquhar KS, Yun J, Frankenberger CA, Bevilacqua E, Yeung K, Kim EJ, Balázsi G,
Rosner MR: Network of mutually repressive metastasis regulators can promote cell heterogeneity and
metastatic transitions. . 2014;  (3): E364-73  | Proc Natl Acad Sci U S A 111 PubMed Abstract Publisher Full
 Text
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response 01 Dec 2015
, University of Adelaide, AustraliaDerek Abbott
The authors respond to Professor Balázsi's suggestions as follows:
In clinical terms, spontaneous regression is an exceedingly rare event that an individual
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In clinical terms, spontaneous regression is an exceedingly rare event that an individual
clinician might perhaps be lucky enough to observe in an entire career of clinical practice -
many do not. As such, it is therefore far less than the CR rates that we have identified and
reported here in this meta-analysis, and the CR rates are most likely to be the effect(s) of
treatment.
We agree that molecular mechanisms and gene regulation are important aspects in
neoplasia and oncogenesis, but these aspects are not precisely central to the subject of our
meta-analysis, and so we did not stray into those areas in this paper
This is an interesting point, however, since we necessarily confined our studies to the time
period from 2000 - 2007, we did not see a trend over that short time. However, the
suggestion is a particularly interesting one and potentially relevant over a longer period. This
is an open question for future study.
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This is a fascinating review by Ashdown and colleagues that examines the CR rate to various cytotoxic
regimens for various cancers as part of meta-analysis focusing on the attainment of CR. The remarkable
concordance of CR rate across cancer and therapy types is very intriguing. The authors explore possible
explanations for this phenomenon and surmise it is most likely immune in nature. This is a remarkable
finding that begs for some solution and to my knowledge is a novel observation.
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it is of an acceptable scientific standard.
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